A Lipid Prodrug Strategy Enhances Targeted Protein Degrader CNS Pharmacokinetics.

Authors

Georges A Leconte, Gillian E Gadbois, Yadira Sepulveda, Ady Schwarz, Erin Chang, Raymond T Suhandynata, Jeremiah D Momper, Fleur M Ferguson

Published in

Journal of medicinal chemistry. Aug 05, 2025. Epub Aug 05, 2025.

Abstract

Targeted protein degraders that recruit the von Hippel-Lindau E3-ligase complex often have poor physicochemical properties, requiring extensive medicinal chemistry optimization prior to use in hypothesis-testing experiments in vivo and with few blood-brain barrier permeable examples disclosed. In this study, we systematically examine a panel of fatty acid promoieties as agents to enhance degrader pharmacokinetics and BBB-exposure. We characterize effects on cellular E3-ligase engagement, cellular BRD4 degradation kinetics, murine plasma stability, and murine blood plasma and brain pharmacokinetics and pharmacodynamics. We identify degrader prodrugs with significantly improved CNS exposure relative to the parent degrader. This led to successful BRD4 degradation in perfused brain samples, demonstrating that fatty acid promoieties can accelerate progress toward proof of principle in vivo experiments for CNS degrader projects.

PMID:
40763185
Bibliographic data and abstract were imported from PubMed on 06 Aug 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.